Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab neoadjuvant and adjuvant electroporation trial in advanced hepatocellular carcinoma
2017-004679-29Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Remission of treated nodules and Local recurrence-free survival. Started Apr 2018; status: active.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-004679-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004679-29.